Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results

Critical Reviews in Toxicology

Volumn 42, Issue 8, 2012, Pages 633-652

  Yoon, Miyoung ^a   Campbell, Jerry L ^a   Andersen, Melvin E ^a   Clewell, Harvey J ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

Clearance; Free concentration in vitro; High throughput screening; in vitro toxicity assay in vitro; IVIVE; Kinetics in vivo; Metabolism; PBPK; Reverse dosimetry

Indexed keywords

2 ETHOXYETHANOL; 2 METHOXYETHANOL; ACRYLAMIDE; BENZENE; CAFFEINE; CHEMICAL COMPOUND; CYTOCHROME; DELTAMETHRIN; DIAZEPAM; ENVIRONMENTAL CHEMICAL; ENZYME; ESTRADIOL; ETHYLENE GLYCOL DERIVATIVE; FLUOROURACIL; LINDANE; METHOTREXATE; METHOXYACETIC ACID; PARATHION; PHENOXYACETIC ACID; PHENYTOIN; RECOMBINANT ENZYME; RETINOIC ACID; TOLUENE; VOLATILE ORGANIC COMPOUND;

ACCURACY; CELL BASED TOXICITY ASSAY; CELL LINE; COMPUTER MODEL; DOSIMETRY; ENZYME KINETICS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; KIDNEY CLEARANCE; LIVER CELL; LIVER CLEARANCE; MAXIMUM PLASMA CONCENTRATION; METABOLISM; MICROSOME; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PROCEDURES; PROTEIN BINDING; QUANTITATIVE ANALYSIS; QUANTITATIVE IN VITRO TO IN VIVO EXTRAPOLATION; REVIEW; RISK ASSESSMENT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; EVALUATION STUDIES AS TOPIC; HUMANS; INTESTINES; KIDNEY; KINETICS; LIVER; MODELS, THEORETICAL; RISK ASSESSMENT; TOXICITY TESTS;

EID: 84865271285     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2012.692115     Document Type: Review

References (111)

1. Anthony A, Caldwell J, Hutt AJ, Smith RL. (1987). Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. Food Chem Toxicol 25:799-806.
2. Arms AD and Travis CC (1988). Reference Physiological Parameters in Pharmacokinetics Modeling. US Environmental Protection Agency, EPA 600/6-88/004. Washington, DC.
3. Barratt MD. (2000). Prediction of toxicity from chemical structure. Cell Biol Toxicol 16:1-13.
4. Blaauboer BJ. (2001a). Toxicodynamic modelling and the interpretation of in vitro toxicity data. Toxicol Lett 120:111-123.
5. Blaauboer BJ. (2002). The necessity of biokinetic information in the interpretation of in vitro toxicity data. Altern Lab Anim 30 Suppl 2:85-91.
6. Blaauboer BJ. (2003). The integration of data on physico-chemical properties, in vitro-derived toxicity data and physiologically based kinetic and dynamic as modelling a tool in hazard and risk assessment. A commentary. Toxicol Lett 138:161-171.
7. Blaauboer BJ. (2010). Biokinetic modeling and in vitro-in vivo extrapolations. J Toxicol Environ Health B Crit Rev 13:242-252.
8. Blaauboer BJ, Forsby A, Houston JB, Beckman M, Combes RD, Dejongh J (2000). An integrated approach to the prediction of systemic toxicity using biokinetic models and biological in vitro test methods. Progress in the reduction refinement and replacement of animal experimentation. Amsterdam: Elsevier.
9. Blaauboer BJ, Clewell HJ, Clothier R, Crespi C, Gerson B, Hawksworth G, Kedderis G, Rozman K, Willhite C. (2001b). In vitro methods for assessing acute toxicity: biokinetic determinations. In: ICCVAM, Report of the International Workshop on in vitro methods for assessing acute systemic toxicity. Research Triangle Park, NC: NIEHS, NIH Publication No: 01-4499.
10. Blaauboer BJ, Barratt MD, Houston JB (1999). The integrated use of alternative methods in toxicological risk evaluation. ECVAM integrated testing strategies task force report 1. Altern Lab Anim, 27: 229-237.
11. Bondoc FY, Bao Z, Hu WY, Gonzalez FJ, Wang Y, Yang CS, Hong JY. (1999). Acetone catabolism by cytochrome P450 2E1: studies with CYP2E1-null mice. Biochem Pharmacol 58:461-463.
12. Brown RP, Delp MD, Lindstedt SL, Rhomberg LR, Beliles RP. (1997). Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13:407-484.
13. Campbell A. (2009). Development of PBPK model of molinate and molinate sulfoxide in rats and humans. Regul Toxicol Pharmacol 53:195-204.
14. Chen Y, Liu L, Nguyen K, Fretland AJ. (2011). Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450. Drug Metab Dispos 39:373-382.
15. Chiba M, Ishii Y, Sugiyama Y. (2009). Prediction of hepatic clearance in human from in vitro data for successful drug development. AAPS J 11:262-276.
16. Coecke S, Ahr H, Blaauboer BJ, Bremer S, Casati S, Castell J, Combes R, Corvi R, Crespi CL, Cunningham ML, Elaut G, Eletti B, Freidig A, Gennari A, Ghersi-Egea JF, Guillouzo A, Hartung T, Hoet P, Ingelman-Sundberg M, Munn S, Janssens W, Ladstetter B, Leahy D, Long A, Meneguz A, Monshouwer M, Morath S, Nagelkerke F, Pelkonen O, Ponti J, Prieto P, Richert L, Sabbioni E, Schaack B, Steiling W, Testai E, Vericat JA, Worth A. (2006). Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM workshop 54. Altern Lab Anim 34:49-84.
17. Crow JA, Borazjani A, Potter PM, Ross MK. (2007). Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. Toxicol Appl Pharmacol 221:1-12.
18. De Buck SS, Mackie CE. (2007). Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin Drug Metab Toxicol 3:865-878.
19. DeJongh J, Verhaar HJ, Hermens JL. (1997). A quantitative propertyproperty relationship (QPPR) approach to estimate in vitro tissueblood partition coefficients of organic chemicals in rats and humans. Arch Toxicol 72:17-25.
20. Fagerholm U. (2007). Prediction of human pharmacokinetics-evaluation of methods for prediction of hepatic metabolic clearance. J Pharm Pharmacol 59:803-828.
21. Forsby A, Blaauboer B. (2007). Integration of in vitro neurotoxicity data with biokinetic modelling for the estimation of in vivo neurotoxicity. Hum Exp Toxicol 26:333-338.
22. Gillette JR. (1971). Factors affecting drug metabolism. Ann N Y Acad Sci 179:43-66.
23. Gómez-Lechón MJ, Castell JV, Donato MT. (2007). Hepatocytes-the choice to investigate drug metabolism and toxicity in man: in vitro variability as a reflection of in vivo. Chem Biol Interact 168:30-50.
24. Gómez-Lechón MJ, Donato MT, Castell JV, Jover R. (2003). Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr Drug Metab 4:292-312.
25. Graaf IA, Groothuis GM, Olinga P. (2007). Precision-cut tissue slices as a tool to predict metabolism of novel drugs. Expert Opin Drug Metab Toxicol 3:879-898.
26. Gülden M, Dierickx P, Seibert H. (2006). Validation of a prediction model for estimating serum concentrations of chemicals which are equivalent to toxic concentrations in vitro. Toxicol In Vitro 20:1114-1124.
27. Gülden M, Mörchel S, Seibert H. (2001). Factors influencing nominal effective concentrations of chemical compounds in vitro: cell concentration. Toxicol In Vitro 15:233-243.
28. Gülden M, Mörchel S, Tahan S, Seibert H. (2002). Impact of protein binding on the availability and cytotoxic potency of organochlorine pesticides and chlorophenols in vitro. Toxicology 175:201-213.
29. Gülden M, Seibert H. (1997). Influence of protein binding and lipophilicity on the distribution of chemical compounds in in vitro systems. Toxicol In Vitro 11:479-483.
30. Gülden M, Seibert H. (2003). In vitro-in vivo extrapolation: estimation of human serum concentrations of chemicals equivalent to cytotoxic concentrations in vitro. Toxicology 189:211-222.
31. Hariparsad N, Sane RS, Strom SC, Desai PB. (2006). In vitro methods in human drug biotransformation research: implications for cancer chemotherapy. Toxicol In Vitro 20:135-153.
32. Hestermann EV, Stegeman JJ, Hahn ME. (2000). Serum alters the uptake and relative potencies of halogenated aromatic hydrocarbons in cell culture bioassays. Toxicol Sci 53:316-325.
33. Hewitt NJ, Lechón MJ, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothuis GM, Hengstler JG. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159-234.
34. Hissink AM, Van Ommen B, Krüse J, Van Bladeren PJ. (1997). A physiologically based pharmacokinetic (PB-PK) model for 1,2-dichlorobenzene linked to two possible parameters of toxicity. Toxicol Appl Pharmacol 145:301-310.
35. Hissink EM, Bogaards JJ, Freidig AP, Commandeur JN, Vermeulen NP, van Bladeren PJ. (2002). The use of in vitro metabolic parameters and physiologically based pharmacokinetic (PBPK) modeling to explore the risk assessment of trichloroethylene. Environ Toxicol Pharmacol 11:259-271.
36. Hochman JH, Chiba M, Nishime J, Yamazaki M, Lin JH. (2000). Influence of P-glycoprotein on the transport and metabolism of indinavir in Caco-2 cells expressing cytochrome P-450 3A4. J Pharmacol Exp Ther 292:310-318.
37. Houston JB, Carlile DJ. (1997). Prediction of hepatic clearance from microsomes, hepatocytes, and liver slices. Drug Metab Rev 29:891-922.
38. Houston JB, Galetin A. (2008). Methods for predicting in vivo pharmacokinetics using data from in vitro assays. Curr Drug Metab 9:940-951.
39. Hubatsch I, Ragnarsson EG, Artursson P. (2007). Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2:2111-2119.
40. Imai T. (2006). Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet 21:173-185.
41. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. (2009). The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 5:211-223.
42. Jewell WT, Miller MG. (1999). Comparison of human and rat metabolism of molinate in liver microsomes and slices. Drug Metab Dispos 27:842-847.
43. Jongeneelen FJ, Berge WF. (2011). A generic, cross-chemical predictive PBTK model with multiple entry routes running as application in MS Excel; design of the model and comparison of predictions with experimental results. Ann Occup Hyg 55:841-864.
44. Kedderis GL. (1997). Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 107:109-121.
45. Kedderis GL. (2007). In vitro to in vivo extrapolation of metabolic rate constants for physiologically based pharmacokinetic models. In: Lipscomb, JC, Ohanian EV. (eds.) Toxicokinetics and risk assessment. New York: Informa healthcare.
46. Kedderis GL, Carfagna MA, Held SD, Batra R, Murphy JE, Gargas ML. (1993). Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro. Toxicol Appl Pharmacol 123:274-282.
47. Kedderis GL, Held SD. (1996). Prediction of furan pharmacokinetics from hepatocyte studies: comparison of bioactivation and hepatic dosimetry in rats, mice, and humans. Toxicol Appl Pharmacol 140:124-130.
48. Kedderis GL, Lipscomb JC. (2001). Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol Ind Health 17:315-321.
49. Klopf W, Worboys P. (2010). Scaling in vivo pharmacokinetics from in vitro metabolic stability data in drug discovery. Comb Chem High Throughput Screen 13:159-169.
50. Kluwe WM. (1982). Overview of phthalate ester pharmacokinetics in mammalian species. Environ Health Perspect 45:3-9.
51. Kramer MA, Tracy TS. (2008). Studying cytochrome P450 kinetics in drug metabolism. Expert Opin Drug Metab Toxicol 4: 591-603.
52. Kramer NI. (2010). Measuring, modeling, and increasing the free concentration of test chemicals in cell assays. PhD Thesis. The Netherlands: Utrecht University.
53. Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y. (2010). In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38:1362-1370.
54. Kusuhara H, Sugiyama Y. (2009). In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab Pharmacokinet 24:37-52.
55. Liao KH, Tan YM, Clewell HJ 3rd. (2007). Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal 27:1223-1236.
56. Liebsch M, Traue D, Barrabas C, Spielmann H, Uphill P, Wilkins S, Mcpherson JP, Wiemann C, Kaufmann T, Remmele M, Holzhutter H-G. (2000). The ECVAM prevalidation study on the use of epiderm for skin corrosivity testing. ATLA 28:371-402.
57. Lipscomb JC, Fisher JW, Confer PD, Byczkowski JZ. (1998). In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. Toxicol Appl Pharmacol 152:376-387.
58. Lipscomb JC, Kedderis GL. (2002). Incorporating human interindividual biotransformation variance in health risk assessment. Sci Total Environ 288:13-21.
59. Lipscomb JC, Poet TS. (2008). In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacol Ther 118:82-103.
60. Lipscomb JC, Teuschler LK, Swartout J, Popken D, Cox T, Kedderis GL. (2003). The impact of cytochrome P450 2E1-dependent metabolic variance on a risk-relevant pharmacokinetic outcome in humans. Risk Anal 23:1221-1238.
61. Loizou GD, Jones K, Akrill P, Dyne D, Cocker J. (1999). Estimation of the dermal absorption of m-xylene vapor in humans using breath sampling and physiologically based pharmacokinetic analysis. Toxicol Sci 48:170-179.
62. Loizou G, Hogg A. (2011). MEGen: A Physiologically Based Pharmacokinetic Model Generator. Front Pharmacol 2:56.
63. Louisse J, de Jong E, van de Sandt JJ, Blaauboer BJ, Woutersen RA, Piersma AH, Rietjens IM, Verwei M. (2010). The use of in vitro toxicity data and physiologically based kinetic modeling to predict dose-response curves for in vivo developmental toxicity of glycol ethers in rat and man. Toxicol Sci 118:470-484.
64. Lübberstedt M, Müller-Vieira U, Mayer M, Biemel KM, Knöspel F, Knobeloch D, Nüssler AK, Gerlach JC, Zeilinger K. (2011). HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. J Pharmacol Toxicol Methods 63:59-68.
65. Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC. (2010). Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos 38:2232-2238.
66. McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. (2004). Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos 32:1247-1253.
67. Mendel CM. (1992). The free hormone hypothesis. Distinction from the free hormone transport hypothesis. J Androl 13:107-116.
68. Miners JO, Knights KM, Houston JB, Mackenzie PI. (2006). In vitroin vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
69. Miners JO, Mackenzie PI, Knights KM. (2010). The prediction of drug-glucuronidation parameters in humans: UDPglucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:196-208.
70. Mirfazaelian A, Kim KB, Anand SS, Kim HJ, Tornero-Velez R, Bruckner JV, Fisher JW. (2006). Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat. Toxicol Sci 93:432-442.
71. Natoli M, Leoni BD, D'Agnano I, D'Onofrio M, Brandi R, Arisi I, Zucco F, Felsani A. (2011). Cell growing density affects the structural and functional properties of Caco-2 differentiated monolayer. J Cell Physiol 226:1531-1543.
72. Obach RS. (1999). Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
73. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, Zeldin DC. (2006). The human intestinal cytochrome P450 "pie". Drug Metab Dispos 34:880-886.
74. Paterson S, Mackay D. (1989). Correlation of tissue, blood, and air partition coefficients of volatile organic chemicals. Br J Ind Med 46:321-328.
75. Pelkonen O, Turpeinen M. (2007). In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 37:1066-1089.
76. Ploemen JP, Wormhoudt LW, Haenen GR, Oudshoorn MJ, Commandeur JN, Vermeulen NP, de Waziers I, Beaune PH, Watabe T, van Bladeren PJ. (1997). The use of human in vitro metabolic parameters to explore the risk assessment of hazardous compounds: the case of ethylene dibromide. Toxicol Appl Pharmacol 143:56-69.
77. Plowchalk DR, Teeguarden J. (2002). Development of a physiologically based pharmacokinetic model for estradiol in rats and humans: a biologically motivated quantitative framework for evaluating responses to estradiol and other endocrine-active compounds. Toxicol Sci 69:60-78.
78. Pritchett JJ, Kuester RK, Sipes IG. (2002). Metabolism of bisphenol a in primary cultured hepatocytes from mice, rats, and humans. Drug Metab Dispos 30:1180-1185.
79. Proctor NJ, Tucker GT, Rostami-Hodjegan A. (2004). Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178.
80. Prueksaritanont T, Gorham LM, Hochman JH, Tran LO, Vyas KP. (1996). Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab Dispos 24:634-642.
81. Prusakiewicz JJ, Ackermann C, Voorman R. (2006). Comparison of skin esterase activities from different species. Pharm Res 23:1517-1524.
82. Punt A, Freidig AP, Delatour T, Scholz G, Boersma MG, Schilter B, van Bladeren PJ, Rietjens IM. (2008). A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat.Toxicol Appl Pharmacol 231:248-259.
83. Punt A, Jeurissen SM, Boersma MG, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM. (2010). Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. Toxicol Sci 113:337-348.
84. Punt A, Paini A, Boersma MG, Freidig AP, Delatour T, Scholz G, Schilter B, van Bladeren PJ, Rietjens IM. (2009). Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol Sci 110:255-269.
85. Rostami-Hodjegan A, Tucker GT. (2007). Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 6:140-148.
86. Rotroff DM, Wetmore BA, Dix DJ, Ferguson SS, Clewell HJ, Houck KA, Lecluyse EL, Andersen ME, Judson RS, Smith CM, Sochaski MA, Kavlock RJ, Boellmann F, Martin MT, Reif DM, Wambaugh JF, Thomas RS. (2010). Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci 117:348-358.
87. Rowland M, Benet LZ, Graham GG. (1973). Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123-136.
88. Sambuy Y, De Angelis I, Ranaldi G, Scarino ML, Stammati A, Zucco F. (2005). The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 21:1-26.
89. Schmitt W. (2008). General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro 22:457-467.
90. Seibert H, Mörchel S, Gülden M. (2002). Factors influencing nominal effective concentrations of chemical compounds in vitro: medium protein concentration. Toxicol In Vitro 16:289-297.
91. Shen DD, Kunze KL, Thummel KE. (1997). Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv Drug Deliv Rev 27:99-127.
92. Siissalo S, Laine L, Tolonen A, Kaukonen AM, Finel M, Hirvonen J. (2010). Caco-2 cell monolayers as a tool to study simultaneous phase II metabolism and metabolite efflux of indomethacin,paracetamol and 1-naphthol. Int J Pharm 383:24-29.
93. Siissalo S, Laitinen L, Koljonen M, Vellonen KS, Kortejärvi H, Urtti A, Hirvonen J, Kaukonen AM. (2007). Effect of cell differentiation andpassage number on the expression of efflux proteins in wild type and vinblastine-induced Caco-2 cell lines. Eur J Pharm Biopharm 67:548-554.
94. Siissalo S, Zhang H, Stilgenbauer E, Kaukonen AM, Hirvonen J, Finel M. (2008). The expression of most UDP-glucuronosyltransferases (UGTs) is increased significantly during Caco-2 cell differentiation, whereas UGT1A6 is highly expressed also in undifferentiated cells. Drug Metab Dispos 36:2331-2336.
95. Soars MG, Burchell B, Riley RJ. (2002). In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301:382-390.
96. Teeguarden JG, Barton HA. (2004). Computational modeling of serumbinding proteins and clearance in extrapolations across life stages and species for endocrine active compounds. Risk Anal 24:751-770.
97. Timchalk C, Poet TS. (2008). Development of a physiologically based pharmacokinetic and pharmacodynamic model to determine dosimetry and cholinesterase inhibition for a binary mixture of chlorpyrifos and diazinon in the rat. Neurotoxicology 29:428-443.
98. Tornero-Velez R, Mirfazaelian A, Kim KB, Anand SS, Kim HJ, Haines WT, Bruckner JV, Fisher JW. (2010). Evaluation of deltamethrin kinetics and dosimetry in the maturing rat using a PBPK model. Toxicol Appl Pharmacol 244:208-217.
99. Turpeinen M, Tolonen A, Chesne C, Guillouzo A, Uusitalo J, Pelkonen O. (2009). Functional expression, inhibition and induction of CYP enzymes in HepaRG cells. Toxicol In Vitro 23:748-753.
100. van de Bovenkamp M, Groothuis GM, Meijer DK, Olinga P. (2008). Liver slices as a model to study fibrogenesis and test the effects of antifibrotic drugs on fibrogenic cells in human liver. Toxicol In Vitro 22:771-778.
101. Van de Kerkhof EG, De Graaf IA, Groothuis GM. (2007). In vitro methods to study intestinal drug metabolism. Curr Drug Metab, 8:658-675.
102. Verwei M, van Burgsteden JA, Krul CA, van de Sandt JJ, Freidig AP. (2006). Prediction of in vivo embryotoxic effect levels with a combination of in vitro studies and PBPK modelling. Toxicol Lett 165:79-87.
103. Wetmore BA, Wambaugh JF, Ferguson, SS, Sochaski MA, Rotroff DM, Freeman K, Clewell HJ 3rd, Dix DJ, Andersen ME, Houck KA, Allen B, Judson RS, Singh R, Kavlock RJ, Richard AM, Thomas RS (2011). Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 125:157-174.
104. Wilkinson GR, Schenker S. (1975). Drug disposition and liver disease. Drug Metab Rev 4:139-175.
105. Wilkinson GR, Shand DG. (1975). Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
106. Yang CH, Glover KP, Han X. (2010). Characterization of cellular uptake of perfluorooctanoate via organic anion-transporting polypeptide 1A2, organic anion transporter 4, and urate transporter 1 for their potential roles in mediating human renal reabsorption of perfluorocarboxylates. Toxicol Sci 117:294-302.
107. Yang J, Jamei M, Yeo KR, Rostami-Hodjegan A, Tucker GT. (2007a). Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos 35:501-502.
108. Yang J, Jamei M, Yeo KR, Tucker GT, Rostami-Hodjegan A. (2007b). Prediction of intestinal first-pass drug metabolism. Curr Drug Metab 8:676-684.
109. Yoon M, Madden MC, Barton HA. (2007). Extrahepatic metabolism by CYP2E1 in PBPK modeling of lipophilic volatile organic chemicals: impacts on metabolic parameter estimation and prediction of dose metrics. J Toxicol Environ Health Part A 70: 1527-1541.
110. Zanelli U, Caradonna NP, Hallifax D, Turlizzi E, Houston JB. (2012). Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs. Drug Metab Dispos 40:104-110.
111. Zucco F, Batto AF, Bises G, Chambaz J, Chiusolo A, Consalvo R, Cross H, Dal Negro G, de Angelis I, Fabre G, Guillou F, Hoffman S, Laplanche L, Morel E, Pinçon-Raymond M, Prieto P, Turco L, Ranaldi G, Rousset M, Sambuy Y, Scarino ML, Torreilles F, Stammati A. (2005). An inter-laboratory study to evaluate the effects of medium composition on the differentiation and barrier function of Caco-2 cell lines. Altern Lab Anim 33: 603-618.